Retinoblastoma Phase II Expanded Access Clinical Trial
A phase 2 trial of Topotecan in retinoblastoma, run by Targeted Therapy Technologies, LLC, now recruiting.
Overview
Retinoblastoma Phase II Expanded Access Clinical Trial is a phase 2 interventional study registered as NCT06679634 by Targeted Therapy Technologies, LLC, with 30 participants planned, started 2025-02-21 and due to reach its primary completion in 2029-11. Interventions recorded: Chemoplaque also referred to as Episcleral Topotecan.
Setting
Retinoblastoma Phase II Expanded Access Clinical Trial
Phase
Phase 2
Sponsor
Targeted Therapy Technologies, LLC
Registry
Enrolled
30
Similar pages
not linked directly; found by shared links- TrialPharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms
Shares Topotecan and the tag pipeline.
- TrialA Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
Shares Topotecan and the tag pipeline.
- TrialA Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
Shares Topotecan and the tag pipeline.